Craig-Hallum Initiates Strong Buy on Spruce Biosciences with $140 Price Target as TA-ERT Advances Toward Approval
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.
/ 4 items
#SPRB↓
Oppenheimer Starts Coverage on Spruce Biosciences with Bullish Outlook
Oppenheimer initiates coverage of Spruce Biosciences with an Outperform rating, citing strong FDA signals, accelerated approval potential, and possible acquisition interest from BioMarin.
Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
Spruce Biosciences Stock Soars after Receiving FDA Breakthrough Therapy Status
FDA gave a new drug Breakthrough status to treat fatal Sanfilippo Syndrome B (MPS IIIB), potentially stopping brain damage in kids.